If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma's preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

    • Aptar Pharma

    Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma's innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative free multi-dose eye drop featuring Aptar Pharma's OSD in the United States.

    Following the worldwide trend towards safe, patient-friendly, cost-effective and preservative free multi-dose dispensers such as Aptar Pharma's OSD system, the new over-the-counter (OTC) eye care product is able to maintain its status as the gold standard in lubricant eye drops.

    The first over-the-counter product marketed with OSD in the United States
    The newly released over-the-counter eye drop product relieves dry, red, itchy eyes by providing preservative free eye drops in a revolutionary multi-dose bottle. Aptar Pharma has worked closely with a leading eye care company to improve patient safety, achieve dosing accuracy and maintain product integrity. The proprietary, sterile, lubricant eye drop formulation, contains 10 ml of solution, equivalent to more than 250 drops and claims to remain sterile for up to three months after first use. It is being supported by extensive television advertising and is available nationwide in pharmacies, supermarkets, and other retailers.

    Meeting the needs of patients and consumers

    Dry eye patients and consumers use lubricant eye drops on a regular basis, and often for the rest of their lives. It is well proven that preserved medications may cause unpleasant and sometimes serious side effects.

    Consequently, removing preservatives from the formulation by using Aptar Pharma’s OSD system is appreciated by the increasing number of patients and consumers experiencing eye irritation or allergic responses with preserved formulations.

    Key benefits of Aptar Pharma’s OSD technology platform

    Aptar Pharma’s OSD system is the result of more than 10 years of development for the delivery of preservative free ophthalmic solutions. European patients and consumers have benefited from this technology for years with more than 70 commercial references available on the market.

    For the newly released over-the-counter product, Aptar Pharma’s OSD system delivers the following features:

    • Unrivalled microbiological safety
    • Intrinsic intuitiveness of a squeezable container
    • User friendliness for all age groups due to a low actuation force
    • Precise and reproducible drop ejection
    • Ergonomic and pocket size design

    "The launch of Aptar Pharma’s OSD system in the United States is a welcome event for patients suffering from eye irritations as it offers them significant benefits compared with standard therapy. This is also a very important milestone for Aptar Pharma in its international development strategy," said Matthias Birkhoff, Vice President Business Development for Aptar Pharma’s Consumer Health Care Division.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Frank Robledano Espín
    • Product Info
    • English
    • Created 17 May 2016
    • Modified 17 May 2016
    • Hits 2846